Amisulpride Switching in Schizophrenic Patients Who Showed Suboptimal Effect and/or Tolerability to Current Antipsychotics in a Naturalistic Setting: An Explorative Study
2
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Objective: Despite numerous atypical antipsychotics (AAP) available, many patients with schizophrenia still experience lack of efficacy and persistent side-effects. Switching from one AAP to another with a different side-effect profile has become a common clinical strategy. We aimed to investigate effect of switching to amisulpride in patients who showed suboptimal effect and /or tolerability to current antipsychotics treatment. Methods: This was a 6-week, prospective, multicenter, open-label, flexible-dose study in patients with schizophrenia. Switching to amisulpride was achieved using cross-titration within 7 days (day 1: 300 mg on day 1 then flexibly dosed 400-800 mg/day). The primary end-point measure was proportion of patients achieving improvement in clinical benefit at week 6 based on Clinical Global Impressions-Clinical Benefit (CGI-CB). Secondary endpoints included change in scores in CGI-CB, CGI-Severity (CGI-S), Subjective Satisfaction Scores (SSS), Brief Psychiatric Rating Scale (BPRS), and Simpson and Angus Rating Scale. Results: Among 37 patients switched to amisulpride, 76% completed study and 56.8% had clinical benefit measure by CGI-CB. CGI-CB and CGI-S scores showed significant improvement at week 6 compared to baseline (mean changes of CGI-CB and CGI-S scores: −1.7+1.0, p＜0.0001 and −0.6±0.0, p=0.001, respectively). SSS scores also improved significantly (mean change: 2.1±2.6, p＜0.0001). Mean weight of patients significantly lowered compared to baseline (mean change: −1.2±2.0, p＜0.0001). Conclusion: Patients with schizophrenia who showed suboptimal efficacy or tolerability with their current antipsychotics and thereby switched to amisulpride resulted in clinical benefit in terms of both improved efficacy and tolerability. The small sample size limits generalizability of the study results.
Abstract
Objective: Despite numerous atypical antipsychotics (AAP) available, many patients with schizophrenia still experience lack of efficacy and persistent side-effects. Switching from one AAP to another with a different side-effect profile has become a common clinical strategy. We aimed to investigate effect of switching to amisulpride in patients who showed suboptimal effect and /or tolerability to current antipsychotics treatment. Methods: This was a 6-week, prospective, multicenter, open-label, flexible-dose study in patients with schizophrenia. Switching to amisulpride was achieved using cross-titration within 7 days (day 1: 300 mg on day 1 then flexibly dosed 400-800 mg/day). The primary end-point measure was proportion of patients achieving improvement in clinical benefit at week 6 based on Clinical Global Impressions-Clinical Benefit (CGI-CB). Secondary endpoints included change in scores in CGI-CB, CGI-Severity (CGI-S), Subjective Satisfaction Scores (SSS), Brief Psychiatric Rating Scale (BPRS), and Simpson and Angus Rating Scale. Results: Among 37 patients switched to amisulpride, 76% completed study and 56.8% had clinical benefit measure by CGI-CB. CGI-CB and CGI-S scores showed significant improvement at week 6 compared to baseline (mean changes of CGI-CB and CGI-S scores: −1.7+1.0, p＜0.0001 and −0.6±0.0, p=0.001, respectively). SSS scores also improved significantly (mean change: 2.1±2.6, p＜0.0001). Mean weight of patients significantly lowered compared to baseline (mean change: −1.2±2.0, p＜0.0001). Conclusion: Patients with schizophrenia who showed suboptimal efficacy or tolerability with their current antipsychotics and thereby switched to amisulpride resulted in clinical benefit in terms of both improved efficacy and tolerability. The small sample size limits generalizability of the study results.
참고문헌 (38)
- Wang SM, "Schizophrenia relapse and the clinical usefulness of oncemonthly aripiprazole depot injection", Neuropsychiatr Dis Treat, 10, pp.1605~1611 (2014)
- Tiihonen J, "A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia", Am J Psychiatry, 168, pp.603~609 (2011)
- Jakubovski E, "Prognostic subgroups for remission, response, and treatment continuation in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) trial", J Clin Psychiatry, 76, pp.1535~1545 (2015)
- Altamura AC, "Designing outcome studies to determine efficacy and safety of antipsychotics for ‘real world’ treatment of schizophrenia", Int J Neuropsychopharmacol, 13, pp.971~973 (2010)
- Zhao Z, "Economic outcomes associated with switching individuals with schizophrenia between risperidone and olanzapine: findings from a large US claims database", CNS Drugs, 18, pp.157~164 (2004)
- Fagiolini A, "Switching long acting antipsychoticmedications to aripiprazole long acting once-a-month: expert consensus by a panel of Italian and Spanish psychiatrists", Expert Opin Drug Saf, 15, pp.449~455 (2016)
- Hong J, "Clinical consequences of switching from olanzapine to risperidone and vice versa in outpatients with schizophrenia: 36-month results from the Worldwide Schizophrenia Outpatients Health Outcomes (W-SOHO) study", BMC Psychiatry, 12, pp.218~ (2012)
- Sicras-Mainar A, "Prevalence of metabolic syndrome according to the presence of negative symptoms in patients with schizophrenia", Neuropsychiatr Dis Treat, 11, pp.51~57 (2014)
- Andrade C, "Cardiometabolic risks in schizophrenia and directions for intervention, 1: magnitude and moderators of the problem", J Clin Psychiatry, 77, pp.e844~e847 (2016)
- Lee SY, "A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone", Prog Neuropsychopharmacol Biol Psychiatry, 35, pp.490~496 (2011)
- Kawabe K, "Metabolic status and resistin in chronic schizophrenia over a 2-year period with continuous atypical antipsychotics", Ther Adv Psychopharmacol, 5, pp.271~277 (2015)
- Gupta A, "Metabolic issues in schizophrenic patients receiving antipsychotic treatment", Indian J Clin Biochem, 29, pp.196~201 (2014)
- Chien-Yu Chen, "Effects of Antipsychotics on Bone Mineral Density in Patients with Schizophrenia: Gender Differences", Clinical Psychopharmacology and Neuroscience, 14(3), pp.238~249 (2016), 대한정신약물학회
- Weiden PJ, "The art and science of switching antipsychotic medications, part 2", J Clin Psychiatry, 68, pp.e02~ (2007)
- Réthelyi J, "Comorbidity of metabolic syndrome, diabetes and schizophrenia: theoretical and practical considerations", Orv Hetil, 152, pp.505~511 (2011)
- Kim KS, "Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone", J Clin Psychiatry, 63, pp.408~413 (2002)
- Sparshatt A, "Amisulpride -dose, plasma concentration, occupancy and response: implications for therapeutic drug monitoring", Acta Psychiatr Scand, 120, pp.416~428 (2009)
- Delcker A, "Amisulpride versus haloperidol in treatment of schizophrenic patients--results of a double-blind study", Pharmacopsychiatry, 23, pp.125~130 (1990)
- Puech A, "Amisulpride, and atypical antipsychotic, in the treatment of acute episodes of schizophrenia: a dose-ranging study vs. haloperidol", Acta Psychiatr Scand, 98, pp.65~72 (1998)
- Danion JM, "Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride. Amisulpride Study Group", Am J Psychiatry, 156, pp.610~616 (1999)
- Paillère-Martinot ML, "Improvement of some schizophrenic deficit symptoms with low doses of amisulpride", Am J Psychiatry, 152, pp.130~134 (1995)
- Pani L, "Practical issues with amisulpride in the management of patients with schizophrenia", Clin Drug Investig, 28, pp.465~477 (2008)
- Komossa K, "Amisulpride versus other atypical antipsychotics for schizophrenia", Cochrane Database Syst Rev, (1), pp.CD006624~ (2010)
- Bak M, "Almost all antipsychotics result in weight gain: a meta-analysis", PLoS One, 9, pp.e94112~ (2014)
- Leucht S, "Comparative efficacy and tolerability of 15antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis", Lancet, 382, pp.951~962 (2013)
- Han C, "Aripiprazole augmentation, antidepressant combination or switching therapy in patients with major depressive disorder who are partial- or non-responsive to current antidepressants:a multi-center, naturalistic study", J Psychiatr Res, 49, pp.75~82 (2014)
- Severus E, "Mirroring everyday clinical practice in clinical trial design: a new concept to improve the external validity of randomized double-blind placebo-controlled trials in the pharmacological treatment of major depression", BMC Med, 10, pp.67~ (2012)
- Kaptchuk TJ, "The double-blind, randomized, placebo-controlled trial: gold standard or golden calf?", J Clin Epidemiol, 54, pp.541~549 (2001)
- Guy W, "ECDEU assessment manual for psychopharmacology", US Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs, ~ (1976)
- Ventriglio A, "Metabolic issues in patients affected by schizophrenia: clinical characteristics and medical management", Front Neurosci, 9, pp.297~ (2015)
- Lin CC, "Improved body weight and metabolic outcomes in overweight or obese psychiatric patients switched to amisulpride from other atypical antipsychotics", J Clin Psychopharmacol, 29, pp.529~536 (2009)
- Carrière P, "Amisulpride has a superior benefit", risk profile to haloperidol in schizophrenia:results of a multicentre, double-blind study (the Amisulpride Study Group), 2000, pp.15, 321~329
- Kim SW, "Amisulpride improves obsessive-compulsive symptoms in schizophrenia patients taking atypical antipsychotics: an open-label switch study", J Clin Psychopharmacol, 28, pp.349~352 (2008)
- Kim SW, "Amisulpride versus risperidone in the treatment of depression in patients with schizophrenia: a randomized, open-label, controlled trial", Prog Neuropsychopharmacol Biol Psychiatry, 31, pp.1504~1509 (2007)
- Sheng Min Wang, "Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update", 전남의대학술지, 52(3), pp.159~172 (2016), 의과학연구소
- Wang SM, "Asenapine, blonanserin, iloperidone, lurasidone, and sertindole:distinctive clinical characteristics of 5 novel atypical antipsychotics", Clin Neuropharmacol, 36, pp.223~238 (2013)
- Han C, "Second-generation antipsychotics in the treatment of major depressive disorder: current evidence", Expert Rev Neurother, 13, pp.851~870 (2013)
- Pani L, "The substituted benzamides and their clinical potential on dysthymia and on the negative symptoms of schizophrenia", Mol Psychiatry, 7, pp.247~253 (2002)